Treating mineral metabolism disorders in patients undergoing long hemodialysis: A search for an optimal strategy

Hemodialysis International

Volumn 13, Issue 4, 2009, Pages 526-532

  Jean, Guillaume ^a   Vanel, Thierry ^a   Terrat, Jean Claude ^a   Hurot, Jean Marc ^a   Lorriaux, Christie ^a   Mayor, Brice ^a   Chazot, Charles ^a  

^a Centre de Rein Artificiel de Tassin   (France)

Author keywords

Hemodialysis; Hyperparathyroidism; Mineral metabolism; Phosphate binders; Vitamin D

Indexed keywords

ALFACALCIDOL; ALUMINUM; CALCIFEDIOL; CALCIMIMETIC AGENT; CALCIUM; CALCIUM CARBONATE; CINACALCET; COLECALCIFEROL; LANTHANUM; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; VITAMIN D;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIALYSATE; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; MAJOR CLINICAL STUDY; METABOLIC DISORDER; METABOLIC PARAMETERS; MINERAL METABOLISM; MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM; VITAMIN SUPPLEMENTATION;

AGED; CHELATING AGENTS; CROSS-SECTIONAL STUDIES; HUMANS; HYPERPHOSPHATEMIA; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 70350550177     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2009.00394.x     Document Type: Article

References (35)

1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients. Am J Kidney Dis 1998, 31:607-617.
2. Kalantar-Zadeh K, Kuwae N, Regidor DL. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006, 70:771-780.
3. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int 2003, ((Suppl)):S111-S114.
4. Young EW, Akiba T, Albert JM. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004, 44:34-38.
5. Goodman WG, London G, Amann K. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004, 43:572-579.
6. Goodman WG, Goldin J, Kuizon BD. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342:1478-1483.
7. Okuno S, Ishimura E, Kitatani K. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis 2007, 49:417-425.
8. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:1-201.
9. Wald R, Tentori F, Tighiouart H, Zager PG, Miskulin DC. Impact of the kidney disease outcomes quality initiative (KDOQI) clinical practice guidelines for bone metabolism and disease in a large dialysis network. Am J Kidney Dis 2007, 49:257-266.
10. Gonzalez EA, Al-Aly Z, Martin KJ. Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism. Semin Dial 2005, 18:171-174.
11. Torres PU, Prié D, Beck L, Friedlander G. New therapies for uremic secondary hyperparathyroidism. J Ren Nutr 2006, 16:87-99.
12. Holick MF. Vitamin D deficiency in CKD. Am J Kidney Dis 2005, 45:1119-1121.
13. Jean G, Terrat J-C, Vanel T. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 2008, 23:3670-3676.
14. Jean G, Chazot C, Charra B. Hyperphosphataemia and related mortality. Nephrol Dial Transplant 2006, 21:273-280.
15. Gauci C, Moranne O, Fouqueray B. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 2008, 19:1592-1598.
16. Nishizawa Y, Jono S, Ishimura E, Shioi A. Hyperphosphatemia and vascular calcification in end-stage renal disease. J Ren Nutr 2005, 15:178-182.
17. Gutzwiller JP, Schneditz D, Huber AR, Schindler C, Gutzwiller F, Zehnder CE. Estimating phosphate removal in haemodialysis. Nephrol Dial Transplant 2002, 17:1037-1044.
18. Nakanishi S, Kazama JJ, Nii-Kono T. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005, 67:1171-1178.
19. Lindsay RM, Alhejaili F, Nesrallah G. Calcium and phosphate balance with quotidian hemodialysis. Am J Kidney Dis 2003, 42:24-29.
20. Kooman J, Basci A, Pizzarelli F. EBPG guideline on haemodynamic instability. Nephrol Dial Transplant 2007, 22((Suppl 2)):ii22-ii44.
21. Sigrist M, McIntyre CW. Calcium exposure and removal in chronic hemodialysis patients. J Ren Nutr 2006, 16:41-46.
22. Fabrizi F, Bacchini G, Di Filippo S, Pontoriero G, Locatelli F. Intradialytic calcium balances with different calcium dialysate levels. Effects on cardiovascular stability and parathyroid function. Nephron 1996, 72:530-535.
23. Argiles A, Kerr PG, Canaud B, Flavier JL, Mion C. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 1993, 43:630-640.
24. Malberti F, Ravani P. The choice of the dialysate calcium concentration in the management of patients on haemodialysis and haemodiafiltration. Nephrol Dial Transplant 2003, 18((Suppl 7)):vii37-vii40. discussion vii57
25. Jean G, Chazot C, Charra B. Biological evolution of renal osteodystrophy after decreasing dialysate calcium from 1.75 to 1.6 mmol/L. Clin Nephrol 2002, 57:91-92.
26. Young EW, Albert JM, Satayathum S. Predictors and consequences of altered mineral metabolism. Kidney Int 2005, 67:1179-1187.
27. Arenas MD, Alvarez-Ude F, Gil MT. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007, 22:1639-1644.
28. Urena Torres P. Clinical experience with cinacalcet HCl. Nephrol Dial Transplant 2004, 19((Suppl 5)):V27-V33.
29. Jean G, Chazot C, Charra B. 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007, 68:63-64.
30. Jean G, Terrat JC, Vanel T. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients. Nephron Clin Pract 2008, 110:c58-c65.
31. London GM, Guerin AP, Verbeke FH. Mineral metabolism and arterial functions in end-stage renal disease. J Am Soc Nephrol 2007, 18:613-620.
32. Holick MF. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
33. Urena P, de Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999, 55:2141-2156.
34. Moe S, Drueke T, Cunningham J. Definition, evaluation, and classification of renal osteodystrophy. Kidney Int 2006, 69:1945-1953.
35. Rottembourg J, Diab R, Boulechfar H. How to reach and maintain the K/DOQI recommendations for bone and mineral metabolism in patients undergoing haemodialysis. Nephrol Ther 2007, 3:33-42.